AUSTIN, Texas, Aug. 22, 2016 /PRNewswire/ -- Celling Biosciences, the foremost pioneer in point-of-care cell therapies, is opening an international office in Curitiba, Brazil, one of the largest medical markets in the world. Combined with Mexican sales that continue to grow, company leaders are confident that this new office will build a bright future for cell therapies in all of South America.
The international development team will continue discussions with Ireland to manage the European expansion. Celling Dubai's office has yielded information indicating that cell therapy will be well received in the Dubai and East Asian markets.
Kevin Dunworth, CEO of Celling Biosciences, said, "We're very excited about this opportunity, and the timing could not be better with the world's attention focused on the athletes in Rio for the Olympics. I personally started my career internationally in Europe, the Middle East, and South America. So this is a little like coming home for me. Though it took more time than I wanted, the technology we now offer has been well vetted in our own market, and I'm thrilled to bring it to the international stage in a place like Brazil."
While the Brazil office will enter Celling's traditional markets of orthopedics and spine, company representatives say they are excited to continue developing their faster growing segments of pain management and cosmesis. According to Andre Luiz Macias, managing partner of Celling Brazil, "We are very excited about not only the sports medicine applications but also believe the aesthetics opportunity is one of the largest in the world. We have been working closely with the research and development team in Austin, Texas to educate ourselves on the latest technologies for processing and delivering cells to the patient. Our objective is to take the ongoing effort in the U.S. and deliver the same education and scientific excellence to the physicians and patients across Brazil."
Celling Brazil will follow the North American model of relying heavily upon a team of highly trained scientists to educate physicians on the ever expanding potential of autologous cell therapies. The research team has expressed excitement about the incredible opportunity to do clinical studies in Brazil across a wide spectrum of applications including critical limb ischemia, sports related injuries, and procedures for cosmetic rejuvenation of the skin.
Celling Biosciences Brazil
Managing Partner: Andre Luiz Macias
Av. Sete de setembro, 5402 , sala 75
Curitiba - Paraná - Brasil
SOURCE Celling Biosciences